Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON25382
NL-OMON25382Not yet recruitingNot Applicable

Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia andsymptomatic gastrointestinal bleeding, the SAIPAN-trial: a multicenter, randomized, open-label, parallelgroup,superiority trial.

Radboudumc0 sites38 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Radboudumc
Enrollment
38
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •Patients older than 18 years with written informed consent.
  • •- Diagnosis of HHT: either confirmed by genetic testing or the Curacao criteria (definite diagnosis).

Exclusion Criteria

  • •- liver cirrhosis child-pugh C.
  • •- symptomatic cholecystolithiasis (possible side-effect octreotide).

Investigators

Sponsor
Radboudumc

Similar Trials

Active, not recruiting
Phase 1
The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia (a.k.a. Rendu-Osler-Weber disease) patients who suffer from gastrointestinal bleeding.
EUCTR2018-004179-11-NLRadboudumc38
Active, not recruiting
Phase 1
The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia(a.k.a. Rendu-Osler-Weber disease) patients who suffer fromgastrointestinal bleeding.
EUCTR2018-004179-11-DERadboudumc38
Active, not recruiting
Phase 1
Effectiveness of somatostatin analogues for GI bleeding in patients with hereditaryhemorrhagic telangiectasiaHereditary hemorrhagic telangiectasia (HHT), also known as Osler–Weber–Rendu disease(in specific patients with gastrointestinal bleeding and transfusion dependency)MedDRA version: 21.0Level: PTClassification code 10019883Term: Hereditary haemorrhagic telangiectasiaSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2018-004179-11-ITRADBOUD UNIVERSITY MEDICAL CENTER38
Active, not recruiting
Phase 1
The effectiveness of Octreotide in hereditary hemorrhagic telangiectasia (a.k.a. Rendu-Osler-Weber disease) patients who suffer from gastrointestinal bleeding.
EUCTR2018-004179-11-FRRadboudumc38
Recruiting
Phase 3
Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding, the SAIPAN-trial: a multicenter, randomized, open-label, parallelgroup, superiority trial.
NL-OMON46190Radboud Universitair Medisch Centrum18
Onderzoek naar de effectiviteit van... | Clinical Trial